 ROCKVILLE, Md., Oct. 1, 2021 PRNewswire -- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy ALTITUDE to be presented REGENXBIO Inc. Nasdaq: RGNX today announced that data from the RGX-314 clinical trials will be presented in three oral presentations at the American Society of Retina Specialists Annual Meeting taking place in San Antonio, TX, from October 8 to 12, 2021. 